[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 1373 Introduced in Senate (IS)]

<DOC>






118th CONGRESS
  1st Session
                                S. 1373

To increase access to medication for opioid overdose reversal, and for 
                            other purposes.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             April 27, 2023

   Mr. Markey (for himself, Mr. Booker, Mr. Marshall, and Mr. Braun) 
introduced the following bill; which was read twice and referred to the 
          Committee on Health, Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL


 
To increase access to medication for opioid overdose reversal, and for 
                            other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Naloxone Affordability Act of 
2023''.

SEC. 2. GAO STUDY ON NALOXONE ACCESS.

    (a) In General.--Not later than 1 year after the date of the 
enactment of this Act, the Comptroller General of the United States 
shall conduct a study on actions that may be taken to protect access to 
naloxone for individuals seeking to purchase naloxone. Such study shall 
address--
            (1) coverage of naloxone (in any available form) as an 
        over-the-counter product--
                    (A) under a group health plan or group or 
                individual health insurance coverage (as such terms are 
                defined in section 2791 of the Public Health Service 
                Act (42 U.S.C. 300gg-91)); and
                    (B) for individuals entitled to benefits under part 
                A or enrolled under part B of title XVIII of the Social 
                Security Act (42 U.S.C. 1395 et seq.) or receiving 
                medical assistance under a State plan under title XIX 
                of such Act (42 U.S.C. 1396 et seq.) (or a waiver of 
                such plan); and
            (2) the out-of-pocket cost to consumers purchasing naloxone 
        under any such plan or coverage.
    (b) Report.--Not later than 1 year after the date of the enactment 
of this Act, the Comptroller General of the United States shall submit 
to Congress a report that contains the findings of the study conducted 
under subsection (a).
                                 <all>